Recurrent or Metastatic Nasopharyngeal Carcinoma Clinical Trials

9 clinical trials for Recurrent or Metastatic Nasopharyngeal Carcinoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma — RECRUITING · PHASE2
• A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma — RECRUITING · PHASE3
• A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. — RECRUITING · PHASE1
• Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial — RECRUITING · PHASE2
• Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC — RECRUITING · PHASE2
• Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC — RECRUITING · PHASE2
• A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) — COMPLETED · PHASE2

Refine this search